GRIFOLS SA INH. A EO-,25/ ES0171996087 /
2024-07-05 9:43:28 PM | Chg. +0.376 | Volume | Bid9:59:57 PM | Ask9:59:57 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
9.050EUR | +4.33% | 295 Turnover: 2,637.700 |
8.946Bid Size: 555 | 9.086Ask Size: 555 | 7.43 bill.EUR | - | 99.89 |
GlobeNewswire
07-01
Grifols’ Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years
GlobeNewswire
06-18
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
GlobeNewswire
06-17
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immu...
GlobeNewswire
04-18
Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at ...
GlobeNewswire
04-04
Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Scree...
GlobeNewswire
2023-11-15
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous ...